Ipsc-based vaccine as a prophylactic and therapeutic treatment for cancer
AssigneesKhloris Biosciences, Inc., The Board of Trustees of the Leland Stanford Junior University
InventorsNigel G. Kooreman, Joseph C. Wu, Lynne A. Bui
Life of this patent
Estimating the term…
Abstract
In one embodiment, the application discloses a method for the treatment of cancer in a patient, the method comprises a vaccination of the patient with a vaccine, wherein the vaccine comprises an effective amount of mammalian pluripotent stem cells obtained from an embryonic source or obtained by reprogramming of somatic cells from the patient, wherein the vaccination comprising the step of administering a mammalian pluripotent stem cells to the patient in need thereof; and vaccine formulations for use in the treatment of cancer.
Claims20
A method for the treatment of cancer in a patient, the method comprises a vaccination of the patient with a vaccine, wherein the vaccine comprises an effective amount of mammalian pluripotent stem cells obtained from an embryonic source or obtained by reprogramming of somatic cells from the patient, wherein the vaccination comprising the step of administering mammalian pluripotent stem cells to the patient in need thereof.
A method for the vaccination of a mammal with a pluripotent stem cell cancer vaccine, the method comprising:
- introducing the mammalian pluripotent stem cells from 1) an embryonic source, or 2) by reprogramming from a somatic cell from the recipient;
- and
- providing the recipient with pluripotent stem cells.
A thermally stable vaccine composition comprising an effective amount of mammalian pluripotent stem cells obtained from an embryonic source or obtained by reprogramming of somatic cells from a mammalian, and an adjuvant or an immunological agent to boost the immune response towards the vaccine.
Dependencies are inferred from the claim text.